Vox Markets Logo

Arix Bioscience and Vadim Alexandre on Novacyt, Genedrive, Omega Diagnostics & Avacta

13:06, 3rd June 2020

Vox Media Player

DYOR Disclaimer

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app


On today's Vox Markets Podcast: Arix Bioscience and Vadim Alexandre on Novacyt, Genedrive, Omega Diagnostics & Avacta

Jonathan Tobin, Managing Director, Arix Bioscience (ARIX) FOLLOW discusses recent news released by two of their portfolio investments, Autolus & Harpoon.

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.


Vadim Alexandre, Head of Healthcare at SP Angel discusses:

Novacyt (NCYT) FOLLOW

Genedrive (GDR) FOLLOW

Omega Diagnostics (ODX) FOLLOW

Avacta (AVCT) FOLLOW

(Interview starts at 16 minutes 33 seconds)    

TwitterFacebookLinkedIn

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Recent Articles
Watchlist